Artificial intelligence (AI) is concretely reshaping the landscape and horizons of oncology, opening new important opportunities for improving the management of cancer patients. Analysing the AI-based devices that have already obtained the official approval by the Federal Drug Administration (FDA), here we show that cancer diagnostics is the oncology-related area in which AI is already entered with the largest impact into clinical practice. Furthermore, breast, lung and prostate cancers represent the specific cancer types that now are experiencing more advantages from AI-based devices. The future perspectives of AI in oncology are discussed: the creation of multidisciplinary platforms, the comprehension of the importance of all neoplasms, including rare tumours and the continuous support for guaranteeing its growth represent in this time the most important challenges for finalising the ‘AI-revolution’ in oncology.
Artificial intelligence (AI) is concretely reshaping our lives and it is time to understand its evolution and achievements to model future development strategies. This is true also for oncology and related fields, where AI is now opening new important opportunities for improving the management of cancer patients, as will be highlighted in this perspective paper.
In 1950, Alan Turing was the first that conceives the idea of using computers to mimic intelligent behaviour and critical thinking . In 1956, John McCarthy coined the term ‘artificial intelligence’ as ‘the science and engineering of making intelligent machines’ [1, 2]. AI began as a simple series of ‘if, then rules’, and has advanced in subsequent years for encompassing multifaceted and composite algorithms that perform similarly to the human brain .
Nowadays, AI represents an emerging and rapidly evolving model that regards different scientific fields, also those devoted to the management of cancer patients [2,3,4,5]. It can be seen as a general concept indicating the ability of a machine to learn and recognise patterns and interactions from a sufficient number of representative models, and to use this information for improving the current approach towards the process of decision-making in a specific field [3,4,5].
In precision oncology, AI is reshaping the existing scenario, aiming at integrating the large amount of data derived from multi-omics analyses with current advances in high-performance computing and groundbreaking deep-learning strategies . Notably, the applications of AI are expanding and include new approaches for cancer detection, screening, diagnosis and classification, the characterisation of cancer genomics, the analysis of tumour microenvironment, the assessment of biomarkers with prognostic and predictive purposes and of strategies for follow-up and drug discovery [3,4,5,6].
For better understanding current roles and future perspectives of AI, two important terms/definitions, which are strictly associated with AI, should be enlightened: machine learning and deep learning. Machine learning is a general concept indicating the ability of a machine in learning and thus improving patterns and models of analysis, whereas deep learning indicates a machine-learning method that utilises complex and deep networks to finalise a highly predictive performance [3, 4]. Of note, these two concepts are central also in the AI revolution in the management of cancer patients.
Through a systematic review-based approach, we aim to clarify which are the current applications of AI in oncology-related fields, with a specific focus on already-approved devices. This approach will allow to better understand roles and potentialities of AI in the management of cancer patients, representing also a reliable point of start for discussing the most important future perspectives of AI in this field.
The systematic review-based approach adhered to the PRISMA statement preset protocol . For providing a comprehensive portrait of the current situation of the roles played by AI in the management of cancer patients, a systematic review was performed, investigating the AI-based devices that have already obtained an official approval for entering into clinical practice in oncology and its related fields. To this aim, two authors (C.L. and A.P.) retrieved all AI-based devices that have obtained the Federal Drug Administration (FDA) approval in oncology-related fields, extracting all potential data by searching FDA official databases (https://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm514737.pdf; https://www.fda.gov/media/145022/download; https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/denovo.cfm; https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma.cfm; https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm. Last access for all documents: 05/31/2021. Such data were also integrated with all previous related reviews or commentaries. All data were organised to be separately presented by the specific oncologic areas in the text, as well as in a summary figure (Fig. 1).
Altogether, the search documented the presence of 71 AI-associated or AI-associable devices that have already received an official FDA approval (Table 1), matching data also from previous related reviews [2, 8,9,10]. The oncology-related field that counts for the largest number of AI devices is cancer radiology, with the majority of approved devices (54.9%). It is followed by pathology (19.7%), radiation oncology (8.5%), gastroenterology (8.5%), clinical oncology (7.0%) and gynaecology 1 (1.4%) (Table 1, Fig. 1a). The vast majority of the approved devices (>80%) regarded the complex area of cancer diagnostics.
Regarding the different tumour types that can be investigated by adopting such devices, the majority of them has been conceived for being applied to a wide spectrum of solid malignancies (cancer in general, 33.8%). The specific tumour that counts for the largest number of AI devices is breast cancer (31.0%), followed by lung and prostate cancer (8.5% each), colorectal cancer (7.0%), brain tumours (2.8%) and others (6 types, 1.4% each) (Table 1, Fig. 1b).
Discussion and future perspectives
In this paper, a comprehensive overview on current applications of AI in oncology-related areas is provided, specifically describing the AI-based devices that have already obtained the official approval to enter into clinical practice. Starting from its birth, AI demonstrated its cross-cutting importance in all scientific branches, showing an impressive growth potential for the future. As highlighted in this study, this growth has interested also oncology and related specialties.
In general, the application of the FDA-approved devices has not been conceived as a substitute of classical analysis/diagnostic workflow, but is intended as an integrative tool, to be used in selected cases, potentially representing the decisive step for improving the management of cancer patients. Currently, in this field, the branches where AI is gaining a larger impact are represented by the diagnostic areas, which count for the vast majority of the approved devices (>80%), and in particular radiology and pathology.
Cancer diagnostics classically represents the necessary point of start for designing appropriate therapeutic approaches and clinical management, and its AI-based refining represents a very important achievement. Furthermore, this indicates that future developments of AI should also consider unexplored but pivotal horizons in this landscape, including drug discovery, therapy administration and follow-up strategies. In our opinion, for determining a decisive improvement in the management of cancer patients, indeed, the growth of AI should follow comprehensive and multidisciplinary patterns. This represents one of the most important opportunities provided by AI, which will allow the correct interactions and integration of oncology-related areas on a specific patient, rendering possible the challenging purposes of personalised medicine.
The specific cancer types that now are experiencing more advantages from AI-based devices in clinical practice are first of all breast cancer, lung cancer and prostate cancer. This should be seen as the direct reflection of their higher incidence compared with other tumour types, but in the future, additional tumour types should be taken into account, including rare tumours that still suffer from the lack of standardised approaches. Since AI is based on the collection and analysis of large datasets of cases, however, the improvement in the treatment of rare neoplasms will likely represent a late achievement. Notably, if together considered, rare tumours are one of the most important category in precision oncology . Thus, in our opinion, ongoing strategies of AI development cannot ignore this tumour group; although the potential benefits seem far away, it is already time to start collecting data on rare neoplasms.
One of the most promising expectancy for AI is the possibility to integrate different and composite data derived from multi-omics approaches to oncologic patients. The promising tools of AI could be the only able to manage the big amount of data from different types of analysis, including information derived from DNA and RNA sequencing. Along this line, the recent release of American College of Medical Genetics standards and guidelines for the interpretation of the sequence variants  has fostered a new wave of AI development, with innovative opportunities in precision oncology (https://www.businesswire.com/news/home/20190401005976/en/Fabric-Genomics-Announces-AI-based-ACMG-Classification-Solution-for-Genetic-Testing-with-Hereditary-Panels; last access 09/21/2021). In our opinion, however, the lack of ground-truth information derived from protected health- data repositories still represents a bottleneck in evaluating the accuracy of AI applications for clinical decision-making.
Overall considered, AI is providing a growing impact to all scientific branches, including oncology and its related fields, as highlighted in this study. For designing new development strategies with concrete impacts, the first steps are representing by knowing its historical background and understanding its current achievements. As here highlighted, AI is already entered into the oncologic clinical practice, but continuous and increasing efforts should be warranted to allow AI expressing its entire potential. In our opinion, the creation of multidisciplinary/integrative developmental views, the immediate comprehension of the importance of all neoplasms, including rare tumours and the continuous support for guaranteeing its growth represent in this time the most important challenges for finalising the ‘AI-revolution’ in oncology.
All data are available in the paper.
Kaul V, Enslin S, Gross SA. History of artificial intelligence in medicine. Gastrointest Endosc. 2020;92:807–12.
Hamamoto R, Suvarna K, Yamada M, Kobayashi K, Shinkai N, Miyake M, et al. Application of artificial intelligence technology in oncology: towards the establishment of precision medicine. Cancers (Basel). 2020;12:3532.
Bhinder B, Gilvary C, Madhukar NS, Elemento O. Artificial intelligence in cancer research and precision medicine. Cancer Disco. 2021;11:900–15.
Kann BH, Hosny A, Aerts HJWL. Artificial intelligence for clinical oncology. Cancer Cell. 2021;39:916–27.
Huynh E, Hosny A, Guthier C, Bitterman DS, Petit SF, Haas-Kogan DA, et al. Artificial intelligence in radiation oncology. Nat Rev Clin Oncol. 2020;17:771–81.
Benzekry S. Artificial intelligence and mechanistic modeling for clinical decision making in oncology. Clin Pharmacol Ther. 2020;108:471–86.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.
Wu E, Wu K, Daneshjou R, Ouyang D, Ho DE, Zou J. How medical AI devices are evaluated: limitations and recommendations from an analysis of FDA approvals. Nat Med. 2021;27:582–4.
Muehlematter UJ, Daniore P, Vokinger KN. Approval of artificial intelligence and machine learning-based medical devices in the USA and Europe (2015–20): a comparative analysis. Lancet Digit Health 2021;3:e195–e203.
Benjamens S, Dhunnoo P, Meskó, B. The state of artificial intelligence-based FDA-approved medical devices and algorithms: an online database. NPJ Digit Med. 2020;3:118.
Luchini C, Lawlor RT, Milella M, Scarpa A. Molecular tumor boards in clinical practice. Trends Cancer. 2020;6:738–44.
Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–24.
This study is supported by Associazione Italiana Ricerca sul Cancro (AIRC 5x1000 n. 12182); Fondazione Cariverona: Oncology Biobank Project “Antonio Schiavi” (prot. 203885/2017); Fondazione Italiana Malattie Pancreas (FIMP-Ministero Salute J38D19000690001); Italian Ministry of Health (RF CO-2019-12369662: CUP: B39C21000370001).
Ethics approval and consent to participate
Not applicable (review—personal perspective).
Consent to publish
Not applicable (review—personal perspective).
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Luchini, C., Pea, A. & Scarpa, A. Artificial intelligence in oncology: current applications and future perspectives. Br J Cancer 126, 4–9 (2022). https://doi.org/10.1038/s41416-021-01633-1
This article is cited by
Cancer care at the time of the fourth industrial revolution: an insight to healthcare professionals’ perspectives on cancer care and artificial intelligence
Radiation Oncology (2023)
Nature Reviews Gastroenterology & Hepatology (2023)
Irish Journal of Medical Science (1971 -) (2023)
Journal of Cancer Research and Clinical Oncology (2023)
Ki-67 assessment of pancreatic neuroendocrine neoplasms: Systematic review and meta-analysis of manual vs. digital pathology scoring
Modern Pathology (2022)